Results 11 to 20 of about 79,208 (292)

JAK2, the JAK2 V617F mutant and cytokine receptors

Pathologie Biologie, 2007
Recently, a unique recurrent somatic mutation was identified as a major molecular event in polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis. Expression of this mutant in cytokine-dependent hematopoietic cell lines induces autonomous growth. This effect is enhanced by overexpression of cytokine receptors, and can be inhibited by
J, Staerk, A, Kallin, Y, Royer, C C, Diaconu, A, Dusa, J-B, Demoulin, W, Vainchenker, S N, Constantinescu   +7 more
openaire   +3 more sources

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors [PDF]

Cell Reports, 2013
To design rational therapies for JAK2-driven hematological malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2.
Michaela Waibel, Vanessa S. Solomon, Deborah A. Knight, Rachael A. Ralli, Sang-Kyu Kim, Kellie-Marie Banks, Eva Vidacs, Clemence Virely, Keith C.S. Sia, Lauryn S. Bracken, Racquel Collins-Underwood, Christina Drenberg, Laura B. Ramsey, Sara C. Meyer, Megumi Takiguchi, Ross A. Dickins, Ross Levine, Jacques Ghysdael, Mark A. Dawson, Richard B. Lock, Charles G. Mullighan, Ricky W. Johnstone   +21 more
doaj   +4 more sources

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias [PDF]

Genes & Development, 2018
Activating JAK2 point mutations are implicated in the pathogenesis of myeloid and lymphoid malignancies, including high-risk B-cell acute lymphoblastic leukemia (B-ALL). In preclinical studies, treatment of JAK2 mutant leukemias with type I JAK2 inhibitors (e.g., Food and Drug Administration [FDA]-approved ruxolitinib) provided limited single-agent ...
Kim, S-K, Knight, DA, Jones, LR, Vervoort, S, Ng, AP, Seymour, JF, Bradner, JE, Waibel, M, Kats, L, Johnstone, RW   +9 more
core   +5 more sources

Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas [PDF]

Modern Pathology, 2009
The Janus kinase 2 (JAK2)-signal transducers and activators of transcription (STAT) pathway plays an important role in hematological malignancies. Mutations and translocations of the JAK2 gene, mapped at 9p24, lead to constitutive activation of JAK2 and its downstream targets.
Meier, Cecile, Hoeller, Sylvia, Bourgau, Caroline, Hirschmann, Petra, Schwaller, Juerg, Went, Philip, Pileri, Stefano A., Reiter, Andreas, Dirnhofer, Stephan, Tzankov, Alexandar   +9 more
openaire   +5 more sources

Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction

Scientific Reports, 2017
JAK2 activation is crucial for cytokine receptor signal transduction and leukemogenesis. However, the underlying processes that lead to full activation of JAK2 are unclear.
Chun-Shan Liu, Hsin-Fang Yang-Yen, Ching-Shu Suen, Ming-Jing Hwang, Jeffrey Jong-Young Yen   +4 more
doaj   +2 more sources

JAK2 Negative Polycythemia Vera

Journal of Laboratory Physicians, 2010
ABSTRACTPolycythemia vera (PV) is a stem cell disorder, characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Several reasons suggest that a mutation on the Janus kinase-2 gene (JAK2) is the most probable candidate gene involved in PV pathogenesis, as JAK2 is directly involved in intracellular signaling, following its exposure ...
Geetha, J P, Arathi, C A, Shalini, M, Srinivasa Murthy, A G   +3 more
openaire   +3 more sources

Papel de la activación leucocitaria y plaquetaria en la trombosis de los síndromes mieloproliferativos crónicos [PDF]

, 2008
[spa] INTRODUCCIÓN Y OBJETIVOS: La causa fundamental de la trombosis en la policitemia vera y la trombocitemia esencial es el aumento de la viscosidad sanguínea secundaria a la eritrocitosis así como el incremento del número de plaquetas y las ...
Álvarez Larrán, Alberto
core   +6 more sources

JAK2 Mutation Assessment in Thrombotic Events at Unusual Anatomical Sites: Insights from a High-Altitude Cohort [PDF]

International Journal of General Medicine
Husain Yahya Alkhaldy,1 Ayel Omar Yahya,2 Abdullah Mohammed Algarni,3 Omayma SE Bakheet,4 Mohammed Assiri,3 M Saboor5,6 1Department of Internal Medicine, College of Medicine, King Khalid University, Abha, Saudi Arabia; 2Division of Adult Hematology, King
Alkhaldy HY, Yahya AO, Algarni AM, Bakheet OSE, Assiri M, Saboor M   +5 more
doaj   +1 more source

PREFERENTIAL NUCLEAR ACCUMULATION OF JAK2V617F IN CD34+ BUT NOT IN GRANULOCYTIC, MEGAKARYOCYTIC OR ERYTHROID CELLS OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA. [PDF]

, 2010
Recently, Dawson et al. identified a previously unrecognized nuclear role for JAK2 in the phosphorylation of the tyrosine 41 of the histone H3 with the exclusion of HP1a from chromatin and resulting in a disregulation of several JAK2-regulated genes such
Rinaldi, Ciro Roberto
core   +2 more sources

JAK2 Inhibitors: Are They the Solution? [PDF]

Clinical Lymphoma Myeloma and Leukemia, 2011
The discovery of the JAK2V617F mutation in patients with Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN) started the era of targeted therapy for these diseases. Until now, patients had few treatment options available, which usually were restricted to hydroxyurea, interferon preparations, and chemotherapy in more aggressive cases ...
Fabio P S, Santos, Srdan, Verstovsek
openaire   +2 more sources